Colistin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Colistin
- Pharmacist Assessment Report
- Colistin: Polymyxin antibiotic that disrupts the Gram-negative outer membrane → postinfectious vasculitis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Colistin: Polymyxin antibiotic that disrupts the Gram-negative outer membrane → postinfectious vasculitis
One-Sentence Summary
Colistin is a polymyxin antibiotic that acts on the outer membrane of Gram-negative bacteria. The TxGNN model predicts it may be effective for postinfectious vasculitis, but the data compiled for this report contain no clinical trials and no publications on this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | postinfectious vasculitis |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Colistin belongs to the polymyxin class, which is known to disrupt the outer membrane of Gram-negative bacteria and kill them.
Postinfectious vasculitis is an immune-mediated inflammatory condition that develops after an infection. Antibacterial activity would not be expected to treat it, because the problem is the immune response rather than a live pathogen. No plausible mechanistic link has been identified, so the high score reflects a statistical pattern in the model, not a biological rationale. Colistin’s known risks to the kidneys and nervous system add further concern.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Colistin is marketed in India. The local data list at least 20 valid single-ingredient registrations, and this list may be partial. Products come as injections (vials of 1, 2, 3 and 4.5 million IU), syrups, dry syrups, suspensions and an oral suspension. Approved indication text is not recorded in the local data.
Safety Considerations
- Disease-level cautions (relation records, not label text): Colistin has recorded contraindication relations with kidney disease, myasthenia gravis and other neuromuscular junction diseases, Clostridium difficile colitis, perinatal necrotizing enterocolitis, herpes simplex infection, and several other conditions. For infection-related hemolytic uremic syndrome, a related prediction in this analysis, colistin’s nephrotoxicity is a particular concern.
- No drug interaction data were found.
Please refer to the package insert for further safety information, as label warnings and contraindications are not available in the compiled data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there is no clinical, literature or mechanistic support for colistin in postinfectious vasculitis. The condition is immune-mediated, and colistin’s nephrotoxicity and neurotoxicity make speculative use unattractive.
To proceed, the following is needed:
- A plausible biological rationale linking colistin to post-infectious immune vasculitis
- Any preclinical or clinical studies that directly address this disease
- Mechanism of action data and package insert warnings and contraindications
- A nephrotoxicity and neurotoxicity risk assessment for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.